Johnson & Johnson (JNJ)
Healthcare
Drug Manufacturers - General
248.80 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Aktien.Guide
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
570.3Mrd. $
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
2,407Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.8%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
0.2
Performance
Perf. 1M
Price performance over the last month.
12.00%
Perf. 3M
Price performance over the last 3 months.
8.10%
Perf. 6M
Price performance over the last 6 months.
25.80%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
16.80%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-2.7%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
29.5
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
22.7
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
5.1
P/B
Price-to-book ratio: market value relative to book equity.
7.6
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
5.9
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
19.8
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
32.0
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
68.0%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
27.4%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
21.8%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
26.4%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
8.4%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
40.4%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
1.7
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
7.62
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 von 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
9.90%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
-52.90%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
6.05%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
6.66%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
9.80%
Dividend
Dividend Yield
Annual dividend divided by the current price: what percentage of your investment comes back as a payout each year.
2.04%
Dividend Per Share (TTM)
Sum of dividends paid per share over the last 12 months.
5.24$
Payout Ratio
Share of profit paid out as dividends. Over 100% means the company is paying out more than it earns — not sustainable long-term.
48.8%
Years Without a Cut
How many years in a row the dividend hasn't been cut — a measure of reliability.
55Years
Increase Streak
How many years in a row the dividend has been raised — the gold standard for dividend payers.
53Years
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
68
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
14
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 von 9
Fundamental Rating
Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.
B (+11 von 100)
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
7.62
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.41 | -15.10 | 22,520 | 5.30 | 15.20 | 6,983 | 4,838 |
| 2025: Q1 | 4.54 | 238.80 | 21,893 | 2.40 | 50.20 | 4,174 | 3,379 |
| 2025: Q2 | 2.29 | 18.30 | 23,743 | 5.80 | 23.30 | 3,878 | 2,480 |
| 2025: Q3 | 2.12 | 91.20 | 23,993 | 6.80 | 21.50 | 9,169 | 8,381 |
| 2025: Q4 | 2.10 | 48.40 | 24,564 | 9.10 | 20.80 | 7,309 | 5,472 |
| 2026: Q1 | 2.14 | -52.80 | 24,062 | 9.90 | 21.80 | 2,514 | 1,465 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Johnson & Johnson erforscht, entwickelt, fertigt und vertreibt mit seinen Tochtergesellschaften weltweit eine Reihe von Produkten im Gesundheitsbereich. Es ist in zwei Segmenten tätig: Innovative Medicine und MedTech.
| Employees | 138,200 |
|---|---|
| Headquarters | New Brunswick, NJ |
| Website | jnj.com |
| IPO Date | 24. Sep 1944 |
| Next Earnings | 15. Jul 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joaquin Duato | CEO & Chairman | 1963 |
| Joseph James Wolk CPA | Executive VP & CFO | 1967 |
| Jennifer L. Taubert | Executive VP & Worldwide Chairman of Innovative Medicine | 1964 |
| John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine and R&D | 1958 |
| Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 1970 |
| Robert J. Decker Jr. | Controller & Chief Accounting Officer | 1973 |
| James Swanson | Executive VP & Chief Information Officer | 1966 |
| Dirk Brinckman | Chief Compliance Officer | – |
| Elizabeth Forminard J.D. | Executive VP & Chief Legal Officer | 1971 |
| Kristen Blair Mulholland | Executive VP & Chief Human Resources Officer | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.